摘要
Major depressive disorder (MDD) is one of the major insurances of suffering globally, but around one-third of the patients show inadequate responses to ordinary monoaminergic antidepressants. Ongoing studies present sufficient evidence that immune dysfunction and neuroinflammation are important for the pathophysiology of MDD for many patient subpopulations. Studies presented y meta-analyses consistently show the presence of increased amounts of C-reactive protein, interleukin-6, and tumor necrosis factor-? in people with MDD, while one out of four patients experiences low-grade inflammation. Longitudinal studies, Mendelian randomization, and immune challenges provide enough reason to say that inflammation has a causative role, primarily in the development of anhedonia, fatigue, and other symptoms associated with neurovegetative disorders. Positron emission tomography of the translocator protein, the analysis of the cerebrospinal fluid and post-mortem studies show that the involvement of glia in the MDD pathophysiology is confirmed; however, it is essential to note that these studies have specific methodological limitations. From a mechanistic perspective, peripheral inflammatory signals primarily derived from everyday stress, early trauma, obesity, unhealthy lifestyle, gut microbiota disorders affect the brain through different ways of influence, as well as through a compromised blood-brain barrier. Thus, activated microglia and activated astrocytes, as well as NLRP3 inflammasome and purinergic P2X7 signaling provoke the development of pathways resulting in the redirection of tryptophan metabolism for the creation of neurotoxic kynurenine products, a decrease in the level of monoamines, an increase in the level of extracellular glutamate, development of glucocorticoid resistance and worsening of neuroplasticity processes. This review aims at summarizing and critically analyzing information about these mechanisms and therapeutic techniques used for combating MDD, including non-steroidal anti-inflammatory drugs, cytokine-targeted biologics, minocycline, omega-3 2 7 acid, drugs affecting the kynurenine pathway, drugs affecting the activities of the receptors mentioned above and many more. According to clinical trials, the efficacy of treatment is substantially available only in the case of individuals with increased inflammatory markers, which calls for the implementation of biomarker-based immunopsychiatry.